Literature DB >> 11978497

Animal model pharmacokinetics and pharmacodynamics: a critical review.

D Andes1, W A Craig.   

Abstract

Animals have been extensively used in the evaluation of antimicrobials. The value of animals in the pharmacokinetic and pharmacodynamic characterization of antimicrobials is critically reviewed. Animal studies have demonstrated that the pharmacokinetic/pharmacodynamic (PK/PD) target determining efficacy can vary for different classes of antimicrobials. However, the magnitude of the target required for bacteriological efficacy is relatively similar for various sites of infection, various pathogens and various drugs within the same class, provided free drug levels are used.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11978497     DOI： 10.1016/s0924-8579(02)00022-5

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


  118 in total

1.  In Vivo Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin against Klebsiella pneumoniae in a Neutropenic Murine Lung Infection Model.

Authors:  Yu-Feng Zhou; Meng-Ting Tao; Wei Huo; Xiao-Ping Liao; Jian Sun; Ya-Hong Liu
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 2.  In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.

Authors:  David Andes
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

3.  Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.

Authors:  Alison K Meagher; Alan Forrest; Axel Dalhoff; Heino Stass; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

4.  Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.

Authors:  Roland R Regoes; Camilla Wiuff; Renata M Zappala; Kim N Garner; Fernando Baquero; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

5.  Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies.

Authors:  Eric L Haseltine; Holly Kimko; Haobin Luo; John Tolsma; Doug J Bartels; Tara L Kieffer; Varun Garg
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-20       Impact factor: 2.745

6.  Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.

Authors:  Ken Coleman; Premavathy Levasseur; Anne-Marie Girard; Monica Borgonovi; Christine Miossec; Henri Merdjan; George Drusano; David Shlaes; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

Review 7.  [Pharmacokinetics and pharmacodynamics of antibiotic therapy].

Authors:  S Beck; S G Wicha; C Kloft; M G Kees
Journal:  Anaesthesist       Date:  2014-10       Impact factor: 1.041

8.  Minocycline modulates neuroinflammation independently of its antimicrobial activity in staphylococcus aureus-induced brain abscess.

Authors:  Tammy Kielian; Nilufer Esen; Shuliang Liu; Nirmal K Phulwani; Mohsin M Syed; Napoleon Phillips; Koren Nishina; Ambrose L Cheung; Joseph D Schwartzman; Jorg J Ruhe
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

9.  Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.

Authors:  Johan W Mouton; Nieko Punt; Alexander A Vinks
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

10.  Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans.

Authors:  Scott W Mueller; Tyree H Kiser
Journal:  Curr Fungal Infect Rep       Date:  2011-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.